Nanotechnology Now

Our NanoNews Digest Sponsors


Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Alltracel Pharmaceuticals Plc - Re Agreement

Abstract:
Alltracel Announces a NanopeuticsTM Product and Technology Development License Agreement with HemCon Medical Technologies to Serve the Military Market

Up front license fees and products expected to be on the market by 2008

Alltracel Pharmaceuticals Plc - Re Agreement

Dublin, Ireland and London, UK | Posted on July 19th, 2007

Alltracel Pharmaceuticals Plc., ("Alltracel", or "the Company"), (AIM:AP.L), the Healthcare Innovation Group focused on the Woundcare, Oral Care, Dermal Health and Cardiovascular Health markets, today announces its NanopeuticsTM subsidiary has signed a licensing agreement for its technology with HemCon Medical Technologies, Inc., the haemorrhage control market leaders in military markets.

Following the successful completion of product concept testing in the US and the Czech Republic in Q2 NanopeuticsTM has agreed a technology development agreement focused on Chitosan- based NanospiderTM technology for advanced woundcare applications in all relevant markets.

An undisclosed license payment is payable immediately and will develop into a royalty revenue model for the completed Chitosan-NanospiderTM products which are expected to reach the market by 2008.

Commenting on the announcement, Tony Richardson, Alltracel's Chief Executive Officer said;

"The NanopeuticsTM technology has been well received in the market place, and today's announcement that HemCon Medical have decided to license our technology underpins the full potential it offers. HemCon is the leading haemorrhage control company serving the military markets and we are excited that we will be working together with their team to bring the NanospiderTM technology to market by 2008."

####

About Alltracel Pharmaceuticals Plc.
Alltracel, (AIM: AP.L) ( http://www.alltracel.com ) the Healthcare Innovation Group is focused on taking proprietary technology from research right through to commercialisation in the global healthcare market.

Alltracel Pharmaceuticals Plc., ("Alltracel") was founded in 1996 and is a public company which listed on London's Alternative Investment Market in July 2001.

With corporate headquarters in Dublin, Ireland; Alltracel has a commercial office in London, England; R&D subsidiary in the Czech Republic and manufacturing facilities in Shenzhen, China. Alltracel also has a wide network of research, development and manufacturing partners in Europe, Asia and North America.

Alltracel operates via two main divisions Alltracel Healthcare Group and Alltracel Healthcare Technologies:

Alltracel Healthcare Group is focused on the commercialisation effort behind proven innovative technologies and services for the global healthcare market. Alltracel Healthcare Group has a range of stake holdings, joint ventures and wholly owned business units operating in a variety of healthcare categories including Wound Care, Oral Care, and Cardiovascular Health.

- Alltracel's specialist Oral Care subsidiary Westone ( http://www.westoneproducts.com ) is headquartered in London, England and is the leading contract supply and manufacturing partner for the European private label inter-dental market. Westone also partners with a number of leading oral care brands internationally.

- Alltracel's specialist Nanotechnology subsidiary Nanopeutics s.r.o. ( http://www.nanopeutics.net ) is headquartered in Liberec in the Czech Republic and is dedicated to the commercialisation of NanospiderTM technology for the global healthcare market.

Alltracel Healthcare Technologies specialises in innovation, research, development and the deployment of proprietary technology in the global healthcare market. Alltracel Healthcare Technologies has established a substantial intellectual property portfolio with patents in a number of healthcare applications areas such as Wound Care, Cardiovascular Health and Skin Care.

m-docTM & PhytopeuticsTM are trademarks of Alltracel Pharmaceuticals plc.

NanospiderTM and NanopeuticsTM are trademarks controlled by Nanopeutics s.r.o.

This information is provided by RNS
The company news service from the London Stock Exchange

For more information, please click here

Contacts:
Dublin: Karen Muldowney
Alltracel: +353 1 235 2162


London: Deborah Scott
Financial Dynamics: +44 207 831 3113

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

A drop of water as a model for the interplay of adhesion and stiction June 30th, 2016

How cancer cells spread and squeeze through tiny blood vessels (video) June 30th, 2016

Building a smart cardiac patch: 'Bionic' cardiac patch could one day monitor and respond to cardiac problems June 28th, 2016

Nanoscientists develop the 'ultimate discovery tool': Rapid discovery power is similar to what gene chips offer biology June 25th, 2016

Announcements

A drop of water as a model for the interplay of adhesion and stiction June 30th, 2016

No need in supercomputers: Russian scientists suggest a PC to solve complex problems tens of times faster than with massive supercomputers June 30th, 2016

Surprising qualities of insulator ring surfaces: Surface phenomena in ring-shaped topological insulators are just as controllable as those in spheres made of the same material June 30th, 2016

How cancer cells spread and squeeze through tiny blood vessels (video) June 30th, 2016

Military

Nanoscientists develop the 'ultimate discovery tool': Rapid discovery power is similar to what gene chips offer biology June 25th, 2016

Ultrathin, flat lens resolves chirality and color: Multifunctional lens could replace bulky, expensive machines June 25th, 2016

Scientists engineer tunable DNA for electronics applications June 21st, 2016

Marrying superconductors, lasers, and Bose-Einstein condensates: Chapman University Institute for Quantum Studies (IQS) member Yutaka Shikano, Ph.D., recently had research published in Scientific Reports June 20th, 2016

New-Contracts/Sales/Customers

Oxford Instruments and Dresden High Magnetic Field Laboratory collaborate to develop HTS magnet technology components for high field superconducting magnet systems June 29th, 2016

Nanometrics Selected for Third-Generation 3D-NAND Process Control: Atlas® Systems Extend Advanced Device Manufacturing Capability June 14th, 2016

Industrial Nanotech, Inc. Signs Agreement With and Receives First Purchase Order from Major New Customer in China June 6th, 2016

Deep Space Industries and SFL selected to provide satellites for HawkEye 360’s Pathfinder mission: The privately-funded space-based global wireless signal monitoring system will be developed by Deep Space Industries and UTIAS Space Flight Laboratory May 26th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic